Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468439 | 0.78 | KDM1A (0.46) | KDM1AMAOBTSHRTDP1MEN1 | |
| SCHEMBL3423844 | 0.77 | KDM1A (0.42) | KDM1AMAOBTSHRTDP1MEN1 | |
| SCHEMBL9058890 | 0.77 | MEN1 (0.44) | KDM1AMAOBTSHRMEN1KMT2A | |
| SCHEMBL29527149 | 0.76 | KDM1A (0.41) | KDM1AMAOBTSHRTDP1MEN1 | |
| SCHEMBL5674631 | 0.76 | HDAC9 (0.44) | KDM1AMAOBTSHRTDP1HDAC9 | |
| SCHEMBL7743674 | 0.75 | KDM1A (0.41) | KDM1AMAOBTSHRTDP1MEN1 | |
| SCHEMBL29784907 | 0.74 | KDM1A (0.53) | KDM1AMAOBTSHRTDP1MEN1 | |
| SCHEMBL6267106 | 0.74 | KDM1A (0.53) | KDM1AMAOBTSHRTDP1MEN1 | |
| SCHEMBL7445452 | 0.74 | KDM1A (0.46) | KDM1AMAOBTSHRTDP1MEN1 | |
| SCHEMBL2465794 | 0.74 | KDM1A (0.46) | KDM1AMAOBTSHRTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825317-B2 | HISTONE DEACETYLASE INHIBITOR, A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I MOLECULE EXPRESSION-PROMOTING AGENT AND ANTICANCER AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20020120099-A1 | Novel cyclic tetrapeptide derivatives and pharmaceutical uses thereof | JAPAN ENERGY CORPORATION (JP) | 2002-08-29 | — | — | US | disclosed |
| EP-1174438-A1 | NOVEL CYCLIC TETRAPEPTIDE DERIVATIVES AND USE THEREOF AS DRUGS | Japan Energy Corporation (JP) | 2002-01-23 | — | — | EP | disclosed |
| US-4061628-A | Intermediates for producing semi-synthetic penicillins and cephalosporins and methods of production | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
| US-3997532-A | Intermediates for producing semi-synthetic cephalosporins | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120099-A1 | Novel cyclic tetrapeptide derivatives and pharmaceutical uses thereof | MICA, HDAC11, HDAC1 | KDM1A 272/4885MAOB 4027/4885TSHR 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.